Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Split Stock

NEW YORK (GenomeWeb News) – Invitrogen announced yesterday that its board of directors has approved a two-for-one stock split.
 
The Carlsbad, Calif.-based firm said that shareholders of record on May 16 will receive on May 27 one additional share for each share held. The company had approximately 48.9 million shares of common stock outstanding as of the end of the first quarter on March 31.
 
Invitrogen’s shares closed at $93.57 in Wednesday trade on the Nasdaq.
 
Its stock has traded between $67.47 and $99.15 over the past 52 weeks, with a high of $99.15 reached on Dec. 10.
 
Last week, the firm reported that its first-quarter revenues rose 13.5 percent and its profit nearly doubled.
 

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.